NL-OMON39976已完成2 期
A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment (CAUY922A2207) - CAUY922A2207
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* 18 years and above.
- •* Histologically or cytologically documented stage IIIB or IV NSCLC.
- •* EGFR gene mutation in the tumor.
- •* Documented clinical benefit (CR, PR, or SD for *6 months) on prior EGFR TKI followed by documented progression.
- •* Patients must have received platinum based prior treatment.
- •* WHO performance status 0-1.
- •* Measurable disease.
排除标准
- •* More than two prior lines of antineoplastic therapy for advanced disease.
- •* Evidence of CNS involvement. Brain CT/MRI mandatory. Note: treated and stable CNS metastasis allowed.
- •* Radiation therapy for management of local disease within four weeks (RT for palliative pain management is allowed).
- •* Prior treatment with an HSP90 inhibitor.
- •* Impaired cardiac function (see protocol page 34 for details).
- •* Women of childbearing potential not using adequate contraception, pregnancy, lactation.
- •* Sexually active men not using adequate contraception.
研究者
相似试验
进行中（未招募）
1 期
An open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutationsSCLCEUCTR2012-001050-25-PLovartis Pharma Services AG120
进行中（未招募）
1 期
An open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutationsSCLCEUCTR2012-001050-25-NOovartis Pharma Services AG59
进行中（未招募）
不适用
An open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutationsSCLCEUCTR2012-001050-25-NLovartis Pharma Services AG108
进行中（未招募）
不适用
An open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutationsEUCTR2012-001050-25-ITOVARTIS FARMA120
进行中（未招募）
不适用
An open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutationsSCLCEUCTR2012-001050-25-ESovartis Farmaceutica S.A120